Investing Profile

John McKearn

InvestorVC
Venture Capital / BioPharma R&D
rivervest.com/team-member/joh...United States
Photo of John McKearn, Managing Director at RiverVest
Your Intro Paths to John McKearn

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Find John McKearn on

cb
Current Investing Position
RiverVest Managing Director
Investment Range
$100K - $10.0M
Sweet Spot
$1M
Investments On Record
15
Current Fund Size
$184.4M

John McKearn is on these Sector & Stage Rankings

John McKearn's Investments On Record (9)

CompanyStageDateRound SizeTotal Raised
OncoResponse
Series UnknownMay 2023$14M
$110M
Co-investors: Wende Hutton (Canaan Partners)
Bonum Therapeutics
Series ANov 2022$93M
$93M
Co-investors: Karl Handelsman (Codon Capital), Samuel Bjork (Digitalis Ventures), Monique Schiersing (Roche Venture Fund)
Good Therapeutics
Series BDec 2021$8M
$30M
Co-investors: Samuel Bjork (Digitalis Ventures), Monique Schiersing (Roche Venture Fund)
Wugen
Series BJul 2021$170M
$170M
Co-investors: Bali Muralidhar (Abingworth)
Allakos
Series BDec 2017$100M
Series ASep 2014$10M
Series AAug 2014$25M
$290M
Co-investors: Paul Walker (New Enterprise Associates (NEA)), Farah Champsi (InterWest)
Arch Oncology
Series AAug 2016$86M
$86M
Co-investors: Carole Nuechterlein (Roche Venture Fund), Jill carroll (SR One), Peter Moldt (Novo Ventures)
Otonomy
Series DApr 2014$49M
Series CSep 2013$46M
Series BAug 2010$39M
Series BAug 2010$39M
$180M
Co-investors: Chau Khuong (OrbiMed), Niall O’Donnell (RiverVest), Jay Lichter (Avalon Ventures), Peter Bisgaard (Pivotal bioVenture Partners), Bill Harrington (Osage University Partners), Brian Dovey (Domain Associates), Heather Preston
ZS Pharma
Series DMar 2014$55M
Series COct 2012$46M
$100M